Governance

Call for Applications

Chair, Board of Directors

The Chair will serve a three-year term starting January 1, 2026, with the option to renew for one additional term. Ideal candidates should have a successful track record in a leadership position, extensive knowledge of and experience in nephrology, experience in clinical trials for drugs/biologics/devices development, and experience pursuing precompetitive collaborations that improve regulatory evaluation of biomedical products. Additionally, past participation with KHI initiatives and a track record of fostering partnerships across various constituencies—including industry, academia, patients, and government—is crucial. Broad knowledge of the kidney community is preferred (e.g., clinicians, industry, patients, researchers, advocacy organizations, regulatory agencies).

Key Responsibilities:

• Ensure effective Board of Directors governance through consortium oversight and serve as the Board's representative to external partners and communities.
• Oversee strategic direction and ensure progress on short- and long-term goals, in partnership with the Board of Directors and ASN Council.
• Integrate and amplify the voice of people with kidney diseases into product development and research through KHI.
• Foster relationships with synergistic programs and initiatives.
• Lead Board of Directors meetings and chair the Strategy Committee, which serves as the Executive Committee of the Board of Directors.
• Identify and advance committee recommendations for Board of Directors consideration.
• Coordinate across KHI's Board of Directors Biologics, Devices, and Drugs Committees to ensure fulfillment of responsibilities.
• Ensure compliance with KHI's Conflict of Interest Policy.

Learn More!

KHI Board of Directors (BOD)

The KHI BOD is charged with executing the consortium's mission and objectives. Meet the Board of Directors!

KHI Board of Directors Governance Update

Given KHI's growth over the past 10 years, a task force was launched in 2022 to assess its governance and oversight structure, recognizing the need to represent the diverse interests of a large member community. Recommendations addressed increased member engagement in KHI activities and projects, and clear prioritization criteria aligned with a multi-year strategy. As approved by the KHI Board of Directors, KHI's governance structure was revised to include four standing committees:

• Strategy Committee
• Biologics Committee (includes xenotransplantation; cellular, tissue, and gene therapies; and vaccines)
• Devices Committee (includes devices, diagnostics, and digital health)
• Drugs Committee

Recommendations also included defined charge and governance of these committees and frameworks for defining KHI strategy and approving KHI activities.

KHI Board of Directors Governance Task Force Executive Summary

For more details on the recommendations, read the Executive Summary here.

KHI Patient and Family Partnership Council (PFPC)

The KHI PFPC advises and makes recommendations on projects and other activities to ensure that the voice, experiences, and involvement of people with kidney diseases are included in the development of kidney drugs, devices, and biologics. Meet the Patient and Family Partnership Council!